HK Stock Market Move | MeiG Smart Technology (03268) surged over 13%, expanding into new products with intelligent body AI modules and entering the cloud-based reasoning market, opening up new opportunities.
SmartCore (03268) rose more than 13% during the trading session. As of the time of writing, it is up 11.05% at HKD 18.99, with a trading volume of HKD 41.6043 million.
MeiG Smart Technology (03268) rose more than 13% in midday trading, up 11.05% to HK$18.99 as of the time of publication, with a turnover of HK$41.6043 million.
On the news front, on July 15, the Cyberspace Administration of China publicly disclosed information on the filing of 7 mobile terminal end-generated artificial intelligence services. Some experts believe that this means that the previously rapidly growing and blurry boundary of end-side large model competition has been officially brought into the track of standardized operation, with clearer industry access standards. In addition, the 2026 World Artificial Intelligence Congress and Global Governance Summit will be held from July 17 to 20 in Shanghai's Expo, Zhangjiang, and Xiyuan "three places and four pavilions". During the conference, more than 1,100 companies will showcase over 3,000 exhibits, with over 300 products making their global debut.
Sinolink previously pointed out that the company has been deeply cultivating high computing power modules, and has successfully run large models such as Stable Diffusion at the module end, taking the lead in the hardware landing competition of generative AI. At the same time, it continues to improve its general digital transmission module product sequence, seizing opportunities for the upgrade of 5G Redcap modules, NTN satellite communication modules, 5G-A modules, and terminals. It is expanding into the fields of smart equipment, consumer IoT, cellular networking PCs, end-side servers, cloud computing data centers, and so on. Shanxi believes that in the short term, the increase in storage prices may slow down downstream demand growth, but expanding into new products for intelligent body AI modules and entering cloud-side inference may open up new space.
Related Articles

JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
.png)
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).

UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
.png)
RECOMMEND





